Literature DB >> 15941672

Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study.

Sophie Tassan-Mangina1, Daniela Codorean, Marie Metivier, Brigitte Costa, Chantal Himberlin, Christelle Jouannaud, Anne Marie Blaise, Jacques Elaerts, Pierre Nazeyrollas.   

Abstract

AIM OF THE STUDY: To evaluate the short and long-term effects of anthracycline chemotherapy in adults using conventional echocardiography and pulsed tissue Doppler imaging (TDI). METHODS AND
RESULTS: Twenty patients were included of which 16 had a complete follow up. They underwent an echocardiography before chemotherapy, 1-3 months and 3.5+/-0.6 years after the treatment. We recorded pulsed TDI at the mitral annulus, the basal segments of the left ventricular (LV) lateral and posterior walls; peak velocities in systole (Sm), early (Em) and late diastole and the isovolumic relaxation time (IVRT) were measured. The cumulative dose of doxorubicin was 211+/-82 g/m2. Early after anthracycline therapy, we observed changes in the diastolic LV function with a decrease of the mitral E peak velocity and TDI Em. At the late control, diastolic changes were more pronounced and associated with an alteration of the systolic function (LV ejection fraction and Sm). Four patients had a LV ejection fraction <50%; in these patients we observed a mitral annulus IVRT <80 ms at the early control; this could be of interest to predict later impairment of the LV ejection fraction.
CONCLUSION: We found early changes in LV diastolic function and observed that late impairment of the LV ejection fraction occurred frequently after anthracycline therapy, despite normal systolic LV function during the first months of follow-up.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15941672     DOI: 10.1016/j.euje.2005.04.009

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  64 in total

Review 1.  Early detection of chemotherapy-related left ventricular dysfunction.

Authors:  Jeanne M DeCara
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

2.  Chemotherapy-induced Cardiotoxicity.

Authors:  Maria Florescu; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Bucur)       Date:  2013-03

Review 3.  Cardiotoxicity due to chemotherapy: role of cardiac imaging.

Authors:  Frédéric Poulin; Paaladinesh Thavendiranathan
Journal:  Curr Cardiol Rep       Date:  2015-03       Impact factor: 2.931

Review 4.  Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors.

Authors:  Serhan Kupeli
Journal:  World J Cardiol       Date:  2014-07-26

Review 5.  Chemotherapy and cardiotoxicity.

Authors:  Howard Broder; Roberta A Gottlieb; Norman E Lepor
Journal:  Rev Cardiovasc Med       Date:  2008       Impact factor: 2.930

6.  Anthracycline cardiotoxicity: from bench to bedside.

Authors:  Luca Gianni; Eugene H Herman; Steven E Lipshultz; Giorgio Minotti; Narine Sarvazyan; Douglas B Sawyer
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

7.  Doxorubicin Cardiotoxicity and Cardiac Function Improvement After Stem Cell Therapy Diagnosed by Strain Echocardiography.

Authors:  Maira S Oliveira; Marcos B Melo; Juliana L Carvalho; Isabela M Melo; Mario Sl Lavor; Dawidson A Gomes; Alfredo M de Goes; Marilia M Melo
Journal:  J Cancer Sci Ther       Date:  2013

8.  Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.

Authors:  Timothy C Tan; Marielle Scherrer-Crosbie
Journal:  Curr Cardiovasc Imaging Rep       Date:  2012-12-01

Review 9.  Cardiovascular imaging in cardio-oncology.

Authors:  Amir Abbas Mahabadi; Christoph Rischpler
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

10.  Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.

Authors:  John D Groarke; Toni K Choueiri; David Slosky; Susan Cheng; Javid Moslehi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.